H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts
H.C. Wainwright increased its price target on Biogen to $228 from $194 and reaffirmed a Buy rating, pointing to a broadened drug pipeline across renal, lupus and SMA indications. The firm highlighted the felzartamab AMR program, upcoming LEQEMBI IQLIK PDUFA and SPINRAZA High-Dose adoption as drivers that could shift Biogen's revenue mix despite ong…